Company news

Akebia Therapeutics, Inc. news in 2026

Akebia Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

November 5, 2026

Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin

November 5, 2026

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

October 29, 2026

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week

October 26, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

October 7, 2026

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

October 6, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

September 14, 2026

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

September 1, 2026

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

August 5, 2026

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

August 3, 2026

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

July 29, 2026

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

June 10, 2026

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

May 7, 2026

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

May 4, 2026

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

April 30, 2026

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

April 12, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

April 7, 2026

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

March 31, 2026

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

March 19, 2026

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

March 3, 2026

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

February 25, 2026

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

February 19, 2026

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 3, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2026

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

January 11, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

January 5, 2026

Calls in 2026

Decks in 2026